Susquehanna International Group’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Susquehanna International Group’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,170	Closed	-$7.69K	–	13735
2023 Q1	$7.69K	Sell	30,170 -43,820	-59%	-$39.6K	﹤0.01%	12245
2022 Q4	$87.3K	Buy	73,990 +53,551	+262%	+$113K	﹤0.01%	11073
2022 Q3	$42K	Buy	+20,439	New	+$34.7K	﹤0.01%	12311
2022 Q2	–	Sell	-76,870	Closed	-$301K	–	14383
2022 Q1	$388K	Buy	+76,870	New	+$349K	﹤0.01%	9618
2021 Q4	–	Sell	-77,135	Closed	-$767K	–	14235
2021 Q3	$767K	Buy	+77,135	New	+$763K	﹤0.01%	8245

Susquehanna International Group's PEAR Position: Q2 2023 in Review

Susquehanna International Group sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 30,170 shares — an estimated $7.69K sold.

Susquehanna International Group first reported a position in PEAR in Q3 2021 and held it in 5 quarters. The position peaked at $767K in Q3 2021. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Susquehanna International Group reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Susquehanna International Group sold 30,170 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $7.69K.
Susquehanna International Group first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2021 and held it in 5 quarters.
Susquehanna International Group's Pear Therapeutics, Inc. Class A Common Stock position peaked at $767K in Q3 2021.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.